110 related articles for article (PubMed ID: 27350337)
1. Correlation of EGFR Del 19 with Fn14/JAK/STAT signaling molecules in non-small cell lung cancer.
Sun Y; Han Y; Wang X; Wang W; Wang X; Wen M; Xia J; Xing H; Li X; Zhang Z
Oncol Rep; 2016 Aug; 36(2):1030-40. PubMed ID: 27350337
[TBL] [Abstract][Full Text] [Related]
2. CHCHD2 is a potential prognostic factor for NSCLC and is associated with HIF-1a expression.
Yin X; Xia J; Sun Y; Zhang Z
BMC Pulm Med; 2020 Feb; 20(1):40. PubMed ID: 32054470
[TBL] [Abstract][Full Text] [Related]
3. Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer.
Al Zobair AA; Al Obeidy BF; Yang L; Yang C; Hui Y; Yu H; Zheng F; Yang G; Xie C; Zhou F; Zhou Y
Oncol Rep; 2013 Apr; 29(4):1524-32. PubMed ID: 23443279
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
Liu L; Qu W; Zhong Z
Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272
[TBL] [Abstract][Full Text] [Related]
6. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.
Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E
Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406
[TBL] [Abstract][Full Text] [Related]
7. PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Yang H; Gao XY; Li P; Jiang TS
Tumour Biol; 2015 Mar; 36(3):2179-84. PubMed ID: 25412952
[TBL] [Abstract][Full Text] [Related]
8. Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.
Skrzypski M; Dziadziuszko R; Jassem E; Szymanowska-Narloch A; Gulida G; Rzepko R; Biernat W; Taron M; Jelitto-Górska M; Marjański T; Rzyman W; Rosell R; Jassem J
Clin Lung Cancer; 2013 Nov; 14(6):666-673.e2. PubMed ID: 23870818
[TBL] [Abstract][Full Text] [Related]
9. Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.
Bai Y; Wang YL; Yao WJ; Guo L; Xi HF; Li SY; Zhao BS
Int J Clin Exp Pathol; 2015; 8(1):824-9. PubMed ID: 25755781
[TBL] [Abstract][Full Text] [Related]
10. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
11. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.
Cortas T; Eisenberg R; Fu P; Kern J; Patrick L; Dowlati A
Lung Cancer; 2007 Mar; 55(3):349-55. PubMed ID: 17161498
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-148b is down-regulated in non-small cell lung cancer and associated with poor survival.
Ge H; Li B; Hu WX; Li RJ; Jin H; Gao MM; Ding CM
Int J Clin Exp Pathol; 2015; 8(1):800-5. PubMed ID: 25755777
[TBL] [Abstract][Full Text] [Related]
13. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
14. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
Liu J; Ping W; Zu Y; Sun W
Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
[TBL] [Abstract][Full Text] [Related]
15. Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer.
Raz G; Allen KE; Kingsley C; Cherni I; Arora S; Watanabe A; Lorenzo CD; Edwards V DK; Sridhar S; Hostetter G; Weiss GJ
Lung Cancer; 2012 May; 76(2):191-6. PubMed ID: 22115706
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
17. The close association between IL‑12Rβ2 and p38MAPK, and higher expression in the early stages of NSCLC, indicates a good prognosis for survival.
Liu Z; Yang W; Yang S; Cai K
Mol Med Rep; 2018 Aug; 18(2):2307-2313. PubMed ID: 29956791
[TBL] [Abstract][Full Text] [Related]
18. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of microRNA-150 is associated with poor prognosis in non-small cell lung cancer.
Yin QW; Sun XF; Yang GT; Li XB; Wu MS; Zhao J
Int J Clin Exp Pathol; 2015; 8(1):842-6. PubMed ID: 25755784
[TBL] [Abstract][Full Text] [Related]
20. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
